EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Hormone Replacement Therapy and Risk for Neurodegenerative Diseases

Richelin V Dye, Karen J Miller, Elyse J Singer, Andrew J Levine

International Journal of Alzheimer's Disease · 2012 · 2012 · 1-18

DOI: 10.1155/2012/258454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Alzheimer's Disease, 2012. Verfasst von Richelin V Dye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Longevity Center, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California, Los Angeles, …. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: NIMH NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past two decades, there has been a significant amount of research investigating the risks and benefits of hormone replacement therapy (HRT) with regards to neurodegenerative disease. Here, we review basic science studies, randomized clinical trials, and epidemiological studies, and discuss the putative neuroprotective effects of HRT in the context of Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and HIV-associated neurocognitive disorder. Findings to date suggest a reduced risk of Alzheimer’s disease and improved cognitive functioning of postmenopausal women who use 17 β -estradiol. With regards to Parkinson’s disease, there is consistent evidence from basic science studies for a neuroprotective effect of 17 β -estradiol; however, results of clinical and epidemiological studies are inconclusive at this time, and there is a paucity of research examining the association between HRT and Parkinson’s-related neurocognitive impairment. Even less understood are the effects of HRT on risk for frontotemporal dementia and HIV-associated neurocognitive disorder. Limits to the existing research are discussed, along with proposed future directions for the investigation of HRT and neurodegenerative diseases.

Autor:innen und Institutionen

  • Longevity Center, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California, Los Angeles, CA 90025, USA.

Förderung

  • NIMH NIH HHS

Zitieren

APA

Dye, R. V., Miller, K. J., Singer, E. J., & Levine, A. J. (2012). Hormone Replacement Therapy and Risk for Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2012, 1-18. https://doi.org/10.1155/2012/258454

Vancouver

Dye RV, Miller KJ, Singer EJ, Levine AJ. Hormone Replacement Therapy and Risk for Neurodegenerative Diseases. International Journal of Alzheimer's Disease. 2012;2012:1-18. doi:10.1155/2012/258454

BibTeX
@article{Dye2012,
  author = {Dye, Richelin V and Miller, Karen J and Singer, Elyse J and Levine, Andrew J},
  title = {Hormone Replacement Therapy and Risk for Neurodegenerative Diseases},
  journal = {International Journal of Alzheimer's Disease},
  year = {2012},
  volume = {2012},
  pages = {1--18},
  doi = {10.1155/2012/258454}
}
Kostenlos starten →